Item
1. Financial Statements
CO
– DIAGNOSTICS, INC.
CONDENSED
CONSOLIDATED BALANCE SHEETS
(Unaudited)
|
|
March 31, 2018
|
|
|
December 31, 2017
|
|
ASSETS:
|
|
|
|
|
|
|
|
|
Current Assets
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
2,541,242
|
|
|
$
|
3,534,454
|
|
Other receivables
|
|
|
23,821
|
|
|
|
—
|
|
Inventory
|
|
|
—
|
|
|
|
9,068
|
|
Prepaid expenses
|
|
|
579,651
|
|
|
|
908,352
|
|
Total current assets
|
|
|
3,144,714
|
|
|
|
4,451,874
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
|
162,852
|
|
|
|
165,567
|
|
Investment in joint venture
|
|
|
19,522
|
|
|
|
44,885
|
|
Total other long-term assets
|
|
|
182,374
|
|
|
|
210,452
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
|
3,327,088
|
|
|
|
4,662,326
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
|
35,742
|
|
|
|
40,819
|
|
Accrued expenses
|
|
|
91,413
|
|
|
|
96,645
|
|
Accrued expenses (related party)
|
|
|
120,000
|
|
|
|
120,000
|
|
Deferred income-current
|
|
|
39,184
|
|
|
|
10,792
|
|
Total current liabilities
|
|
|
286,339
|
|
|
|
268,256
|
|
Long-term Liabilities, net of current portion
|
|
|
|
|
|
|
|
|
Accrued expenses-long-term (related party)
|
|
|
330,000
|
|
|
|
360,000
|
|
Deferred income-long-term
|
|
|
145,458
|
|
|
|
183,546
|
|
Total long-term liabilities
|
|
|
475,458
|
|
|
|
543,546
|
|
Total liabilities
|
|
|
761,797
|
|
|
|
811,802
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS’ EQUITY (DEFICIT):
|
|
|
|
|
|
|
|
|
Common stock, $.001 par value, 180,000,000 shares authorized; 12,326,409 and 12,317,184 shares issued and outstanding, respectively.
|
|
|
12,326
|
|
|
|
12,317
|
|
Additional paid-in capital
|
|
|
16,285,642
|
|
|
|
16,260,651
|
|
Accumulated deficit
|
|
|
(13,732,677
|
)
|
|
|
(12,422,444
|
)
|
Total stockholders’ equity
|
|
|
2,565,291
|
|
|
|
3,850,524
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders’ equity
|
|
$
|
3,327,088
|
|
|
$
|
4,662,326
|
|
See
accompanying notes to condensed consolidated financial statements.
CO
– DIAGNOSTICS, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
|
|
Three Months Ended March 31,
|
|
|
|
2018
|
|
|
2017
|
|
Revenues
|
|
$
|
9,696
|
|
|
$
|
—
|
|
Cost of sales
|
|
|
—
|
|
|
|
—
|
|
Gross profit
|
|
|
9,696
|
|
|
|
—
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
Selling and marketing
|
|
|
95,263
|
|
|
|
64,217
|
|
General and administrative
|
|
|
882,046
|
|
|
|
225,734
|
|
Research and development
|
|
|
297,415
|
|
|
|
265,688
|
|
Depreciation and amortization
|
|
|
12,403
|
|
|
|
9,726
|
|
Total operating expenses
|
|
|
1,287,127
|
|
|
|
564,365
|
|
Loss from operations
|
|
|
(1,277,431
|
)
|
|
|
(564,365
|
)
|
Other income (expense):
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
—
|
|
|
|
(141,377
|
)
|
Interest income
|
|
|
7,561
|
|
|
|
—
|
|
Loss on investment in joint venture
|
|
|
(40,363
|
)
|
|
|
—
|
|
Total other income (expense)
|
|
|
(32,802
|
)
|
|
|
(141,377
|
)
|
Loss before income taxes
|
|
|
(1,310,233
|
)
|
|
|
(705,742
|
)
|
Provision for income taxes
|
|
|
—
|
|
|
|
—
|
|
Net loss
|
|
$
|
(1,310,233
|
)
|
|
$
|
(705,742
|
)
|
Net loss per share – basic and diluted
|
|
$
|
(0.11
|
)
|
|
$
|
(0.07
|
)
|
Weighted average shares - basic and diluted
|
|
|
12,319,030
|
|
|
|
9,882,395
|
|
See
accompanying notes to condensed consolidated financial statements.
CO
– DIAGNOSTICS, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
|
|
Three Months Ended March 31,
|
|
|
|
2018
|
|
|
2017
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(1,310,233
|
)
|
|
$
|
(705,742
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
12,403
|
|
|
|
9,726
|
|
Stock based compensation
|
|
|
25,000
|
|
|
|
6,198
|
|
Accretion of notes payable discount
|
|
|
—
|
|
|
|
41,912
|
|
Other losses
|
|
|
40,363
|
|
|
|
—
|
|
Changes in assets and liabilities:
|
|
|
|
|
|
|
|
|
Decrease in deferred income
|
|
|
(9,696
|
)
|
|
|
—
|
|
Decrease in prepaid and other assets
|
|
|
304,880
|
|
|
|
38,322
|
|
Decrease in inventory
|
|
|
9,068
|
|
|
|
—
|
|
Increase (decrease) in accounts payable and accrued expenses
|
|
|
(40,309
|
)
|
|
|
189,848
|
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
|
(968,524
|
)
|
|
|
(419,736
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
Purchase of property and equipment
|
|
|
(9,688
|
)
|
|
|
(41,046
|
)
|
Investment in joint venture
|
|
|
(15,000
|
)
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
Net cash used by investing activities
|
|
|
(24,688
|
)
|
|
|
(41,046
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
Principal payments on debt (related party)
|
|
|
—
|
|
|
|
(41,500
|
)
|
|
|
|
|
|
|
|
|
|
Net cash used by financing activities
|
|
|
—
|
|
|
|
(41,500
|
)
|
|
|
|
|
|
|
|
|
|
Net decrease in cash
|
|
|
(993,212
|
)
|
|
|
(502,282
|
)
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents beginning of period
|
|
|
3,534,454
|
|
|
|
998,737
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents end of period
|
|
$
|
2,541,242
|
|
|
$
|
496,455
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow information:
|
|
|
|
|
|
|
|
|
Interest paid
|
|
$
|
—
|
|
|
$
|
—
|
|
Income taxes paid
|
|
$
|
—
|
|
|
$
|
—
|
|
See
accompanying notes to condensed consolidated financial statements.
CO
– DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March
31, 2018
(Unaudited)
Note
1 - Basis of Presentation
The
accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally
accepted in the United States of America for interim financial information and with the instructions to Form 10-Q as they are
prescribed for smaller reporting companies. Accordingly, they do not include all the information and footnotes required by accounting
principles generally accepted in the United States of America for complete financial statements. In the opinion of management,
all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading
have been included. Operating results for the three-month period ended March 31, 2018 are not necessarily indicative of the results
that may be expected for the year ending December 31, 2018. These statements should be read in conjunction with the Company’s
audited financial statements and related notes for the year ended December 31, 2017, included in the Company’s Form 10K
Annual Report filed on March 28, 2018.
Certain
2017 financial statement amounts have been reclassified to conform to 2018 presentations.
Description
of Business
Co-Diagnostics,
Inc. (“Company,” “CDI,”), a Utah corporation headquartered in Salt Lake City, Utah, is a molecular diagnostics
company formed in April 2013, that develops, manufactures and markets a new, state-of-the-art diagnostics technology.
CDI’s
diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly
automating historically complex procedures in both the development and administration of tests. CDI’s newest technical advance
involves a novel approach to PCR primer design (cooperative primers) that eliminates one of the key vexing issues of PCR amplification,
the exponential growth of primer-dimer pairs which adversely interferes with identification of the target DNA. In addition CDI
scientists have enhanced the understanding of the mathematics of DNA test design, so as to “engineer” a DNA test and
automate algorithms to screen millions of possible designs to find the optimum DNA test design. CDI’s proprietary platform
of
Co-Dx™
technologies integrates and streamlines these steps as it analyzes biological samples.
Co-Diagnostics’
CoDx™
portfolio of molecular diagnostics development products and tests represents a radical new advancement in the
understanding of the molecular interactions of DNA. The Company uses highly specialized, proprietary cooperative-theory
mathematics
,
leading to a
revolutionary leap forward
in the detection of infectious diseases, genetic disorders and other conditions.
CoDx™
tests are a
fraction of the cost
of other DNA-based tests,
designed for a new generation
of affordable,
mobile point-of-care diagnostic devices and compatible with many other devices, making state-of-the-art diagnostics available
anywhere in the world
, including developing countries.
Recent
Accounting Pronouncements
From
time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective
date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not
have a material impact on the Company’s financial statements upon adoption.
The
Company, an emerging growth company (“EGC”), has elected to take advantage of the benefits of the extended transition
period provided for in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards which
allows the Company to defer adoption of certain accounting standards until those standards would otherwise apply to private companies.
In
March 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-08, Receivables – Nonrefundable Fees
and Other Costs (Subtopic 310-20). The amendments in this update shorten the amortization period for certain callable debt securities
held at a premium. Specifically, the amendments require the premium to be amortized to the earliest call date. The amendments
do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. For
public business entities, the amendments in this update are effective for fiscal years, and interim periods within those fiscal
years, beginning after December 15, 2019, for public EGC companies like us. This update is not expected to have a significant
impact on the Company’s financial statements.
In
August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and
Cash Payments, to clarify guidance on the presentation and classification of certain cash receipts and payments in the statement
of cash flows. This update was issued with the intent of reducing diversity in practice with respect to eight types of cash flows.
This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years,
for public EGC companies like us. The update is not expected to have a significant impact on the Company’s financial statements.
In
February 2016, the FASB issued ASU No. 2016-02 Leases (Topic 842), which requires recognition of leased assets and liabilities
on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual periods and
interim periods with those periods beginning after December 15, 2019, for public EGC companies like us. Management is currently
evaluating the impact that the updated standard will have on its consolidated financial statements and related disclosures.
In
May 2014, the FASB issued ASU No. 2014-09: “Revenue from Contracts with Customers (Topic 606)” which supersedes the
revenue recognition requirements in ASC Topic 605, “Revenue Recognition”, and requires entities to recognize revenue
in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to
which the entity expects to be entitled in exchange for those goods or services. Additional revenue recognition updates were also
issued in 2016 and 2017, which further clarified certain aspects of the new revenue recognition guidance. The new authoritative
guidance is effective for interim and annual periods beginning after December 15, 2018, for public EGC companies like us. The
guidance permits two methods of adoption: retrospectively to each prior reporting period presented (the full retrospective method),
or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application
(the modified retrospective method). The Company is in the process of determining the method of adoption, but the update is not
expected to have a significant impact on the Company’s financial statements since the Company’s revenue is currently
immaterial.
Note
2 - Significant Accounting Policies
Earnings
(Loss) per Share
Basic
earnings or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted
average number of shares outstanding during each period. As the Company experienced net losses during the three months ending
March 31, 2018, and 2017, respectively, no common stock equivalents have been included in the diluted earnings per common share
calculations as the effect of such common stock equivalents would be anti-dilutive. As of March 31, 2018, and 2017, there were
1,028,969 and 2,675,350 potentially dilutive shares, respectively.
Note
3 – Notes Payable
At
March 31, 2018, and December 31, 2017 we had no outstanding notes payable. However, at March 31, 2017, we had an aggregate of
$3,394,484 of current notes payable. For the three months ended March 31, 2017 we included $141,377 of interest expense.
Note
4 – Stock-based Compensation
Stock
Incentive Plans
The Co-Diagnostics, Inc 2015 Long-term
Incentive Plan reserves an aggregate of 6,000,000 shares. The number of unissued stock options authorized under the 2015 Plan
at March 31, 2018 was 5,677,293.
Stock
Options
There
were no options granted in both the three months ended March 31, 2017 and 2018.
For
the three months ended March 31, 2018, there was no stock-based compensation expense related to granted and unexercised stock
options.
For
the three months ended March 31, 2017, the Company recognized $6,198 of stock-based compensation expense, related to stock options,
recorded in our general and administrative department for options vesting which were granted prior to January 1, 2017.
The
following table summarizes option activity during the three months and year ended March 31, 2018 and December 31, 2017, respectively.
|
|
Options Outstanding
|
|
|
Weighted
Average
Exercise
Price
|
|
|
Weighted
Average
Fair
Value
|
|
|
Weighted
Average
Remaining
Contractual
Life (years)
|
|
Outstanding at January 1, 2017
|
|
|
261,372
|
|
|
$
|
0.55
|
|
|
$
|
0.49
|
|
|
|
8.63
|
|
Options granted
|
|
|
63,335
|
|
|
|
3.85
|
|
|
|
1.59
|
|
|
|
4.60
|
|
Expired
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Forfeited options
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Exercised
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Outstanding at December 31, 2017
|
|
|
322,707
|
|
|
$
|
1.29
|
|
|
$
|
0.70
|
|
|
|
7.05
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options granted
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Expired
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Forfeited options
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Exercised
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at March 31, 2018
|
|
|
322,707
|
|
|
$
|
1.29
|
|
|
$
|
0.70
|
|
|
|
6.80
|
|
Warrants
The
following table summarizes warrant activity during the three months and year ended March 31, 2018 and December 31, 2017, respectively.
|
|
Warrants
Outstanding
|
|
|
Weighted Average
Exercise
Price
|
|
|
Weighted Average
Fair
Value
|
|
|
Weighted
Average
Remaining Contractual
Life (years)
|
|
Outstanding at January 1, 2017
|
|
|
111,129
|
|
|
|
8.25
|
|
|
|
0.11
|
|
|
|
4.91
|
|
Warrants issued
|
|
|
595,133
|
|
|
|
2.91
|
|
|
|
1.74
|
|
|
|
4.28
|
|
Expired
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Forfeited warrants
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Exercised
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Outstanding at December 31, 2017
|
|
|
706,262
|
|
|
$
|
3.27
|
|
|
$
|
1.48
|
|
|
|
4.22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants issued
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Expired
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Forfeited warrants
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Exercised
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at March 31, 2018
|
|
|
706,262
|
|
|
$
|
3.27
|
|
|
$
|
1.48
|
|
|
|
3.97
|
|
The
following table summarizes information about stock options and warrants outstanding at March 31, 2018.
|
|
|
Outstanding
|
|
|
Exercisable
|
|
|
|
|
|
|
|
Weighted
Average
Remaining
|
|
|
Weighted
Average
|
|
|
|
|
|
Weighted Average
|
|
Range of Exercise Prices
|
|
|
Number
Outstanding
|
|
|
Contractual
Life (years)
|
|
|
Exercise
Price
|
|
|
Number Exercisable
|
|
|
Exercise
Price
|
|
$
|
0.11-0.55
|
|
|
|
534,099
|
|
|
|
5.72
|
|
|
$
|
0.33
|
|
|
|
534,099
|
|
|
$
|
0.33
|
|
|
2.00-3.85
|
|
|
|
86,355
|
|
|
|
4.38
|
|
|
|
3.31
|
|
|
|
86,335
|
|
|
|
3.31
|
|
|
5.10-7.20
|
|
|
|
408,535
|
|
|
|
3.83
|
|
|
|
5.46
|
|
|
|
408,535
|
|
|
|
5.46
|
|
$
|
0.11-7.20
|
|
|
|
1,028,969
|
|
|
|
4.86
|
|
|
$
|
2.61
|
|
|
|
1,028,969
|
|
|
$
|
2.72
|
|
Note
5 – Related Party Transactions
The
Company acquired the exclusive rights to the Co-Primer technology pursuant to a license agreement dated April 2014, between us
and DNA Logix, Inc., which was assigned to Dr. Satterfield prior to our acquisition of DNA Logix, Inc. On March 1, 2017, the Company
entered into an amendment to its Exclusive License Agreement for its Cooperative Primers (“License”) technology with
Dr. Satterfield, a member of our Board of Directors. The amendment provides in part that all accrued royalties under the License
cease as of January 1, 2017, and we began in January to pay $700,000 of accrued royalties at the rate of $10,000 per month. For
the three months ended March 31, 2017, the Company included $107,500 as an expense for this license agreement in research and
development. At March 31, 2018 the aggregate balance of this liability was $450,000.
Prior
to July 12, 2017 the Company financed operations partly through short-term loans with related parties and through the deferral
of payment to related parties for expenses incurred. At December 31, 2017, the Company accrued $480,000 in expenses for technology
royalties payable to Dr. Satterfield.
Note
6 – Lease Obligations
Our
offices are located at 2401 S Foothill Dr. Suite D Salt Lake City Utah 84109-1479. The space consists of approximately 7,015 square
feet and is leased under a multi-year contract at a rate of $11,109 per month expiring on January 31, 2020. For the three months
ended March 31, 2018 and 2017, the Company expensed $37,897 and $15,125, respectively for rent. The Company’s lease rent
obligation is as follows:
Year
|
|
|
Amount
|
|
2018
|
|
|
$
|
133,308
|
|
2019
|
|
|
|
133,308
|
|
2020
|
|
|
|
11,109
|
|
Total
|
|
|
$
|
277,725
|
|
Note
7 – Subsequent Events.
The
Company evaluated subsequent events pursuant to ASC Topic 855 and has determined that there are no additional events that need
to be reported.
Item
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Cautionary
Note Regarding Forward-Looking Statements
This
report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Rule 175 promulgated thereunder, and Section 21E of the Securities Exchange Act of 1934, as amended, and Rule 3b-6 promulgated
thereunder, that involve inherent risk and uncertainties. Any statements about our expectations, beliefs, plans, objectives, strategies
or future events or performance constitute forward-looking statements. These statements are often, but not always, made through
the use of words or phrases such as “anticipate,” “estimate,” “plan,” “project,”
“continuing,” “ongoing,” “expect,” “believe,” “intend” and similar
words or phrases. Accordingly, these statements involve estimates, assumptions and uncertainties that could cause actual results
to differ materially from those expressed or implied therein. All forward-looking statements are qualified in their entirety by
reference to the factors discussed in this report and to the following risk factors discussed more fully in the Risk Factors in
our annual report on Form 10-K filed with the commission on March 28, 2018:
|
●
|
dependence
on commercialization of our molecular diagnostic technology;
|
|
|
|
|
●
|
our
continued losses;
|
|
|
|
|
●
|
concerns
of customers relating to our financial uncertainty;
|
|
|
|
|
●
|
general
economic and market conditions;
|
|
|
|
|
●
|
ineffective
internal operational and financial control systems;
|
|
|
|
|
●
|
rapid
technological change;
|
|
|
|
|
●
|
intense
competitive factors;
|
|
|
|
|
●
|
our
ability to hire and retain specialized and key personnel;
|
|
|
|
|
●
|
dependence
on the sales efforts of others;
|
|
|
|
|
●
|
uncertainty
of intellectual property protection;
|
|
|
|
|
●
|
potential
infringement on the intellectual property rights of others;
|
|
|
|
|
●
|
extreme
price fluctuations in our common stock;
|
|
|
|
|
●
|
price
decreases due to future sales of our common stock;
|
|
|
|
|
●
|
future
shareholder dilution; and
|
|
|
|
|
●
|
absence
of dividends.
|
Because
the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed or
implied in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any
forward-looking statement. Further, any forward-looking statement speaks only as of the date on which it is made, and we
undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which
the statement is made or to reflect the occurrence of future events or developments. New factors emerge from time to time,
and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on
our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from
those contained in any forward-looking statements.
Critical
Accounting Policies
The
preparation of financial statements in conformity with U.S. GAAP requires that we make estimates and judgments that affect the
reported amounts of assets, liabilities, revenues and expenses and the related disclosure of contingent assets and liabilities.
On an ongoing basis, we evaluate our assumptions and estimates, including those related to recognition of revenue, valuation of
investments, valuation of inventory, valuation of intangible assets, measurement of stock-based compensation expense and litigation.
We base our estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily
apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
As
an
emerging growth company
, we have elected to
opt-in to
the extended transition period for new or revised accounting
standards. As a result, our financial statements may not be comparable to those of companies that comply with public company effective
dates.
Executive
Overview
Co-Diagnostics,
Inc. (“Company,” or “CDI,”), a Utah corporation, is a molecular diagnostics company that has developed,
and intends to sell molecular diagnostic technology such as lab systems (which we refer to as the “MDx device”) and
manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA
or RNA). We will also use our proprietary technology to design specific tests to locate genetic markers for use in industries
other than infectious disease and license the use of those tests to specific customers.
Dr.
Brent Satterfield, our Chief Technology Officer, created the Company’s suite of intellectual properties. Our scientists
use the complex mathematics of DNA test design, to “engineer” a DNA test and to automate algorithms that rapidly screen
millions of possible options on a DNA target strain to pinpoint the optimum design. Dr. Satterfield developed the Company’s
intellectual property consisting of the predictive mathematical algorithms and proprietary reagents used in the testing process,
which together represent a major advance in Polymerase Chain Reaction (“PCR”) testing systems. CDI’s technologies
are now protected by five granted or pending US patents, as well as certain trade secrets. Our platform allows us to avoid paying
existing patent royalties required by other PCR test systems, which has the potential of allowing CDI to sell diagnostic tests
at a lower cost than competitors, while generating a profit margin.
We
will either sell or lease our portable labs to existing diagnostic centers, through sale or lease agreements, and sell reagents
used in our proprietary tests.
We
designed our tests by identifying the optimal locations on the target gene for amplification and paired the location with the
optimized primer and probe structure to achieve outputs that meet the design input requirements identified from market research.
This is done by following planned and documented processes, procedures and testing. In other words, the data resulting from our
tests verify that we succeeded in designing what we intended to at the outset. Verification is a series of testing that concludes
that the product is ready to proceed to validation in a clinical evaluation setting using initial production tests to confirm
that the product as designed meets the user needs.
CDI’s
diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly
automating historically complex procedures in both the development and administration of tests. CDI’s newest technical advance
involves a novel approach to PCR test design (cooperative primers) that eliminates one of the key vexing issues of PCR amplification,
the exponential growth of primer-dimer pairs (false positives and false negatives) which adversely interferes with identification
of the target DNA.
Using
its proprietary test design system and proprietary reagents, CDI will design and sell PCR diagnostic tests for diseases and pathogens
starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, HIV and Zika virus,
all of which tests have been designed and verified in CDI’s laboratory.
Organizational
History and Corporate Information
We
were incorporated as Co-Diagnostics, Inc., in Utah on April 18, 2013. Our principal executive office is located 2401 S. Foothill
Drive, Suite D, Salt Lake City, Utah 84109. Our telephone number is (801) 438-1036. Our web address is http://codiagnostics.com
Product
Offering
Caribbean
and Central and South America
Our
initial sales will be to entities within the Caribbean Public Health Agency Members States (Anguilla, Antigua and Barbuda, Aruba,
Bahamas, Barbados, Belize, Bermuda, BES Islands, British Virgin Islands, Cayman Islands, Curacao, Dominica, Grenada, Haiti, Guyana,
Jamaica, Montserrat, Saint Kitts and Nevis, Saint Lucia, St Maarten, Saint Vincent and the Grenadines, Suriname, Trinidad and
Tobago, Turks and Caicos Islands).
In
some of these countries, there are no regulatory hurdles and we can start offering our tests immediately. The U.S. Food and Drug
Administration (FDA) has granted permission for us to export certain of our tests. The FDA’s permission to export was granted
under Section 801 (e) of the Federal Food, Drug, and Cosmetic Act, as amended (the “FDC Act”). Section 801 (e) of
the Act covers certain medical devices that have not yet received an approved Premarket Approval in the United States by the FDA,
such as our products. Section 801 (e) applies to medical devices that are acceptable to the importing country and that are manufactured
under the FDA’s Good Manufacturing Practices.
We
will first offer our Zika test in this region because of the demand for such test followed quickly by tests for tuberculosis,
hepatitis B and C, dengue then our full range of tests.
India
The
Company has entered into an agreement to manufacture diagnostics tests for seven infectious diseases with a pharmaceutical manufacturing
company in India. The agreement provides for the manufacture of the tests named above and the joint sales and marketing of those
tests in India.
Since
the tests will be conducted in India on Indian citizens, no FDA approval or inspection will be required. Certain Indian regulatory
approval from the Central Drugs Standard Control Organization (CDSCO) must be acquired. We are engaging the services of an experienced
consultant in India to help get us through this process. Research Use Only (RUO) reagents are able to be sold without requiring
regulatory approval as long as they are labeled and designated as such.
India
is the country with the highest burden of tuberculosis. According to the World Health Organization (WHO) tuberculosis statistics
for India for 2015 give an estimated incidence figure of 2.2 million cases of tuberculosis for India out of a global incidence
of 9.6 million. The tuberculosis incidence for India is the number of new cases of active tuberculosis disease in India during
a certain time period (usually a year).
Europe
Most
molecular tests, such as our tests, are governed in Europe by the framework for in vitro diagnostics (IVDs), which encompasses
diagnostic products such as reagents, instruments and systems intended for use in diagnosis of disease. The regulatory system
for IVDs is built largely on a self-certification procedure, placing heavy responsibility on manufacturers. Examples of current
obligations include having in place a qualitative manufacturing process, user instructions that are clear and fit for purpose,
ensuring that the ‘physical’ features of devices and diagnostics do not pose any danger. If a product fulfils these
and other related control requirements, it may be CE-marked as an indication that the product is compliant with EU legislation
and sold in the European Union.
We
have received ISO 13485 and ISO 9001 certifications relating to the design and manufacture of our medical device products. The
ISO certification indicates that we meet the standards required to self-certify certain of our products and affix a CE marking
for sales of our products in countries accepting the CE marking (not in the United States) with only minimal further governmental
approvals in each country. We expect to have our Zika and tuberculosis tests CE-marked in 2018. We estimate the remaining costs
for CE-marks to be approximately $100,000.
United
States
We
do not anticipate offering our tests in the United States in the near future. We believe, however, our tests may be able to qualify
as Laboratory Developed Tests (LDT’s), diagnostic tests that are developed and manufactured by CLIA certified laboratories.
These tests are developed by the lab for use only in that laboratory. CLIA laboratories develop the performance characteristics,
perform the analytical validation for their LDT’s and obtain licenses to offer them as diagnostic services. The FDA has
publicly announced its intention to regulate certain LDTs in a phased-in approach, but draft guidance that was published a couple
of years ago was withdrawn at the end of the Obama administration and replaced by an informal non-enforceable discussion paper
reflecting some of the feedback that it received on LDT regulation.
Market
Opportunity
The
molecular diagnostics market is a fast growing portion of the in vitro (test tube based, controlled environment) diagnostics market.
There are several advantages of molecular tests over other forms of diagnostic testing, which include higher sensitivities, the
ability to perform multiplex tests and the ability to test for drug resistance or individual genes.
Intellectual
Property Protection
Because
much of our future success and value depends on our proprietary technology, our patent and intellectual property strategy is of
critical importance. Three of our initial U.S. patents related to our technology have been granted by the U.S. Patent and Trademark
Office, or PTO. As of March 31, 2018, we had two additional patents pending in the U.S. and foreign counterpart applications.
Two of our issued patents expire in 2034 and the other patent expires in 2036.
We
have identified additional applications of the technology, which represent potential patents that further define specific applications
of the processes that are covered by the original patents. We intend to continue building our intellectual property portfolio
as development continues and resources are available.
We
have copyrighted our development software that can be used by any lab or developer to develop diagnostic tests based on our technology.
RESULTS
OF OPERATIONS
Results
of Operations for the Three Months ended March 31, 2018 and 2017
Revenues
For
the three months ended March 31, 2018 we generated $9,696 of revenues compared to no revenues in the three months ended March
31, 2017. The revenue represented a license fee for licensing our Zika tests and certain other Flaviviruses for limited distribution
to a Canadian company.
Cost
of Revenues
For
the three months ended March 31, 2018 and for the three months ended March 31, 2017, we recorded no costs of revenues.
Expenses
We
incurred total operating expenses of $1,287,127 for the three months ended March 31, 2018 compared to total operating expenses
of $564,365 for the three months ended March 31, 2017. The increase of $722,762 was due primarily to increased business activities
following the completion of our initial public offering. There was an increase in general and administrative expenses of $656,312,
an increase in sales and marketing costs of $31,046, and an increase of $32,727 in our research and development expenses.
General
and administrative expenses increased $656,312 from $225,734 for the three months ended March 31, 2017 to $882,046 for the three
months ended March 31, 2018. The increase was primarily the result of an increase of $310,330 in independent consulting expenses
and an increase of $87,019 in legal and other professional services both of which were incident to factors relating to becoming
a publically traded company and engaging professionals with market related experience. We also experienced an increase of $187,208
in salaries and related benefits, an increase of $41,250 in directors’ fees, an increase of $26,849 in regulatory expenses.
Our office rent increased $8,272 incident to moving into our new offices.
Our
sales and marketing expenses for the three months ended March 31, 2018 were $95,263 compared to sales and marketing expenses of
$64,217 for the three months ended March 31, 2017. The increase of $31,046 is due primarily to an increase of $26,098 in salary
and related benefits expense and an increase of $3,333 in office rent.
Our research and development expenses increased
by $31,727 from $265,688 for the three months ended March 31, 2017 to $297,415 for the three months ended March
31, 2018. The increase was primarily due to an increase of $58,922 in payroll and employee related expenses, an increase of $60,893
in other professional services and an increase in rent expense of $14,949. The increase in expense was partially offset by a decrease
of $107,500 in technology license fees due to a restructuring of our Co-Primer license. The increase in expenses was also partially
offset by a decrease in lab supplies and services expense of $14,088 due to a reimbursement by a customer of lab supplies expense
of approximately $26,000 incurred in the customer’s research project.
Interest
Expense
For
the three months ended March 31, 2018, we incurred no interest expense compared to interest expense for the three months ended
March 31, 2017 of $141,377. The decrease of $141,377 was the result of having our all of our indebtedness retired coincident with
the funding of our initial public offering.
Net
Loss
We realized a net loss for the three months
ended March 31, 2018 of $1,310,233 compared with a net loss for the three months ended March 31, 2017 of $705,742. Of the increase
in net loss of $604,491, $713,066 was the result of the increased operating expenses explained above, partially offset by the
decrease of $141,377 in interest expense and a $40,363 loss on investment related to our joint venture.
Liquidity
and Capital Resources
Liquidity
is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise
operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts
receivable and accounts payable and capital expenditures.
To
date we have financed our operations through sales of common stock and the issuance of debt.
At
March 31, 2018, we had cash and cash equivalents of $2,541,242, total current assets of $3,144,714, total current liabilities
of $286,339 and total stockholders’ equity of $2,565,291. At December 31, 2017, we had cash and cash equivalents of $3,534,454,
total current assets of $4,451,874, total current liabilities of $268,256 and total stockholders’ equity of $3,850,524.
We
experienced negative cash flow used in operations during the three months ended March 31, 2018 of $968,524 compared to negative
cash flow used in operations for the twelve months ended December 31, 2017 of $1,312,267. The negative cash flow was met by cash
reserves remaining from the issuances of common stock incident to the completion of our initial public offering. The amount of
our operating deficit could decrease or increase significantly depending on strategic and other operating decisions, thereby affecting
our need for additional capital. We expect our operating losses will continue until we are able to generate revenue. Until our
operations become profitable, we will continue to rely on proceeds received from our initial public offering. We expect additional
investment capital to come from (i) additional private placements of our common stock with existing and new investors and (ii)
the private placement of other securities with investors similar to those that have provided funding in the past.
Our
monthly cash operating expenses, including our technology research and development expenses and interest expense, were approximately
$322,840 per month during the three months ended March 31, 2018. Our operating expenses increased significantly upon completion
of our initial public offering as we increased development and sales activities in furtherance of our business plan. The foregoing
estimates, expectations and forward-looking statements are subject to change as we make strategic operating decisions from time
to time and as our expenses fluctuate from period to period.
The
amount of our operating deficit could decrease or increase significantly depending on strategic and other operating decisions,
thereby affecting our need for additional capital. We expect our operating expenses will continue until we are able to generate
revenue. Our business model contemplates that revenue will commence in 2018 and our need for additional investment will depend
on the amount of revenue generated.
Our
long-term liquidity is dependent upon execution of our business model and the commencement of revenue generating activities and
working capital as described above, and upon capital needed for continued commercialization and development of our diagnostic
testing technology. Commercialization and future development of diagnostic tests utilizing our PCR technology are expected to
require additional capital estimated to be approximately $1,000,000 annually for the foreseeable future. This estimate will increase
or decrease depending on specific opportunities and available funding.
To
date, we have met our working capital needs primarily through funds received from sales of our common stock and from convertible
debt financings. Until our operations become profitable, we will continue to rely on proceeds received from external funding.
We expect additional investment capital may come from additional private placements of our common stock with existing and new
investors and the private placement of other securities with investors similar to those that have provided funding in the past.
Off-Balance
Sheet Arrangements
We
have no off-balance sheet arrangements.